The Future of AI in Pathology: Transforming Diagnosis & Drug Development | Andrew Beck, PathAI

Andrew Beck, MD, PhD is the Co-founder and CEO of PathAI, where he and his team are developing AI tools to improve the precision of pathology and the efficacy of drug development for diagnosis of cancer and also many other complex diseases.Before founding PathAI, Andrew was an Associate Professor at Harvard Medical School, where his research focused on the application of machine learning to cancer pathology. He earned his MD from Brown University and his PhD in Biomedical Informatics from Stanford University, where he pioneered some of the first computational models used to predict patient outcomes in oncology.Time stamps of the conversation:00:00:00 Highlights00:01:28 Introduction00:02:18 Entrypoint in AI00:07:02 Background in Medicine and Bioinformatics 00:10:00 Leap from academia to entrepreneurship00:16:20 Translating AI developments to Pathology00:21:15 Specialist vs Generalist AI models in medicine00:24:15 What sets PathAI apart?00:26:32 AI adoption medicine00:34:25 Usage of AI tools in clinical workflows, example MASH00:40:10 AI in Dermatopathology00:42:15 AI for biomarker discovery00:47:05 Will AI models replace pathologists?00:52:28 Avoiding over-reliance on AI00:57:40 Is AI living unto the hype?01:01:00 Challenges in clinical trials 01:05:12 AI reaching patients directly01:09:50 Working at intersection of AI & Healthcare01:15:30 Pitfalls to learn fromMore about PathAI: https://www.pathai.com/and Andy: https://www.pathai.com/about-us/andy-beckAbout the Host:Jay is a Machine Learning Engineer III at PathAI working on improving AI for medical diagnosis and prognosis. Linkedin: https://www.linkedin.com/in/shahjay22/Twitter: https://twitter.com/jaygshah22Homepage: https://jaygshah.github.io/ for any queries.Stay tuned for upcoming webinars!***Disclaimer: The information in this video represents the views and opinions of the speaker and does not necessarily represent the views or opinions of any institution. It does not constitute an endorsement by any Institution or its affiliates of such video content.***